Vorasidenib
servier
['cross tumor', 'rectal', 't-dxd', 'vorasidenib']
in nejm group's latest coverage of #asco23:
- selective radiotherapy for rectal cancer
- vorasidenib for idh-mutant glioma
- t-dxd across tumor sites 
Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.